Amendment 3 to the Quality Assurance Agreement, dated as of February 26, 2020, by and between the Company and Bachem AG

This Amendment 3 (the “Amendment 3”) to the Quality Assurance Agreement is made as of February 26, 2020 (the “Effective Date”) by and between Bachem AG, an entity organized under the laws of Switzerland, with its principal place of business at Hauptstrasse 144, CH-4416 Bubendorf, Switzerland (“Bachem”), and Xeris Pharmaceuticals, lnc., an entity organized under the laws of Delaware, with its principal place of business at 180 North LaSalle St, Suite 1600, Chicago, lL 60601, USA ("Xeris").

WHEREAS, Bachem and Xeris have entered into that certain Quality Assurance Agreement between the Parties effective as of November 20, 2015, as amended by Amendment 1 to the Quality Assurance Agreement dated October 31, 2016 (“Amendment 1”), and as further amended by Amendment 2 to the Quality Assurance Agreement dated January 26, 2017 (“Amendment 2”), collectively comprising the “Quality Assurance Agreement”;

WHEREAS, Bachem and Xeris now mutually desire to amend, modify and restate certain terms and conditions of the Quality Assurance Agreement.

NOW THEREFORE, the Parties hereto, intending to be legally bound, agree as follows:

Certain analytical services are provided for Bachem by contract laboratories. All listed subcontractors are appropriately qualified by Bachem and considered to be approved by Xeris. Alternatively, to using a contract laboratory these tests may be performed in house at Bachem provided that the specific technique is available.

IN WITNESS WHEREOF, the Parties have caused this Amendment 3 to the Quality Assurance Agreement to be duly executed by their authorized representatives as of the Effective Date.